InMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Adar1 Capital Management, Llc Acquires 8,021 Shares of Company Stock

Posted by Jeff Wilder on Oct 16th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 8,021 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $10,667.93. Following the completion of the purchase, the insider owned 954,509 shares of the company’s stock, valued at approximately $1,269,496.97. This represents a 0.85% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Thursday, October 15th, Adar1 Capital Management, Llc acquired 984 shares of InMed Pharmaceuticals stock. The shares were acquired at an average cost of $1.32 per share, with a total value of $1,298.88.
On Tuesday, October 13th, Adar1 Capital Management, Llc acquired 564 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.33 per share, with a total value of $750.12.
On Thursday, October 8th, Adar1 Capital Management, Llc acquired 2,256 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.33 per share, with a total value of $3,000.48.
On Wednesday, October 7th, Adar1 Capital Management, Llc bought 3,046 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $4,051.18.
On Tuesday, October 6th, Adar1 Capital Management, Llc bought 5,601 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $7,449.33.
On Monday, October 5th, Adar1 Capital Management, Llc bought 18,182 shares of InMed Pharmaceuticals stock. The shares were bought at an average price of $1.33 per share, for a total transaction of $24,182.06.
On Friday, October 2nd, Adar1 Capital Management, Llc purchased 8,307 shares of InMed Pharmaceuticals stock. The stock was bought at an average price of $1.33 per share, with a total value of $11,048.31.
On Thursday, October 1st, Adar1 Capital Management, Llc purchased 16,431 shares of InMed Pharmaceuticals stock. The stock was bought at an average price of $1.33 per share, with a total value of $21,853.23.
On Monday, September 14th, Adar1 Capital Management, Llc purchased 28,505 shares of InMed Pharmaceuticals stock. The stock was bought at an average cost of $1.29 per share, with a total value of $36,771.45.
On Wednesday, September 16th, Adar1 Capital Management, Llc purchased 8,340 shares of InMed Pharmaceuticals stock. The stock was bought at an average cost of $1.29 per share, with a total value of $10,758.60.

InMed Pharmaceuticals Stock Performance

Shares of InMed Pharmaceuticals stock opened at $1.33 on Friday. InMed Pharmaceuticals Inc. has a one year low of $0.57 and a one year high of $2.33. The company has a market cap of $4.42 million, a price-to-earnings ratio of -0.81 and a beta of 0.93. The business’s 50 day moving average price is $1.38 and its 200 day moving average price is $1.30.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last posted its quarterly earnings results on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, InMed Pharmaceuticals currently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on INM

Hedge Funds Weigh In On InMed Pharmaceuticals

A hedge fund recently bought a new position in InMed Pharmaceuticals stock. Montanova Capital LLC acquired a new position in shares of InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $155,000. Montanova Capital LLC owned about 3.02% of InMed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 20.12% of the company’s stock.

InMed Pharmaceuticals Company Profile

(Get Free Report)

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder.